semaj83/ctmatch_classification huggingface dataset:
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 3.0-999.0,  Pathological Processes in the Posterior Fossa Dura Defects Preoperative Subjects undergoing elective craniotomy / craniectomy for pathological processes in the posterior fossa (such as benign and malignant tumors, vascular malformations, and Chiari 1 malformations) that result in dura defects requiring dura substitution for closure and who are able and willing to comply with the procedures required by the protocol Signed and dated written informed consent from the subject or from his/her legal representative prior to any study-related procedures Age >= 3 years, either gender Intraoperative Surgical Wound Classification Class I and Risk Index Category (RIC) <= 2. Penetration of mastoid air cells during partial mastoidectomy is permitted and will be recorded A patch of autologous fascia or pericranium or suturable collagen-based dura substitute was cut to size and then sutured into the dura defect The hem of native dura exposed along and under the craniotomy edge is wide enough to facilitate suturing and to allow for sufficient surface area for adherence of the investigational product  Preoperative Female subjects who are breastfeeding, pregnant, or intend to become pregnant during the clinical study period Subjects with a dura lesion from a recent surgery that still has the potential for cerebrospinal fluid (CSF) leakage unless it can be expected that the lesion will be excised completely, including all old suture holes Chemotherapy scheduled within 7 days following surgery Radiation therapy to the head scheduled within 7 days following surgery Subjects with severely altered renal (serum creatinine > 2 mg/dL) and/or hepatic function [ALT, AST > 5 x upper limit of norm (ULN)] Evidence of an infection indicated by any one of the following: fever > 101°F, white blood cell (WBC) count < 3500/μL or > 13000/μL, positive blood culture, positive chest X-ray. A positive urine culture (> 10^5 colony-forming units (CFU)/mL) leads to unless acute cystitis is the sole cause. Evidence of infection along the planned surgical path. A WBC count of < 20000/μL is permitted if the patient is being treated with steroids in the absence of all the other infection parameters Conditions compromising the immune system; existence of autoimmune disease Known hypersensitivity to aprotinin or other components of the investigational product Non-compliant or insufficient treatment of diabetes mellitus [glycosylated hemoglobin (HbA1c) > 7.5%]
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Elective Cranial Procedures With Dural Incision Patient is between 18 and 75 years of age Patient is scheduled for an elective cranial procedure that entails a dural incision Evidence of intraoperative non-watertight closure
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 6.0-14.0,  Status Epilepticus Seizures Children presenting convulsing to the pediatric emergency or developing seizure while in casualty Age 6-14 years  Known hypersensitivity to any benzodiazepine Child has received any parenteral anti-convulsant within 1 hr prior to enrollment Presence of severe cardio-respiratory compromise or cardiac arrhythmias Presence of upper respiratory tract infection Presence of basal skull fracture causing cerebro-spinal fluid (CSF) rhinorrhea
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Renal Failure SIRS Sepsis Critically Ill Multiple Organ Dysfunction Syndrome Critically ill, postoperative/posttraumatic patients with threatening acute renal failure  Life expectancy < 24 hours Participation in other trials Known or suspected pregnancy
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Posttraumatic Stress Disorder Diagnosis of Posttraumatic Stress Disorder  Diagnosis of psychosis, drug or alcohol dependency/abuse Unable to fill in questionnaires in Dutch Color blindness (Stroop test)
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Posttraumatic Stress Disorder willingness to participate in a naturalistic treatment study using paliperidone and in two fear conditioning tests, one at baseline and one at the end of the 6 weeks treatment study We will PTSD subjects on medications (possible medications antidepressants, benzodiazepines) who have no or only partial treatment response. Paliperidone will be added to the existing treatment regime which will remain unchanged during the study period. PTSD subjects will have a minimum score of 50 on the Clinician-Administered PTSD Scale (CAPS; Blake et al, 1995)  a comorbid diagnosis of bipolar illness, schizophrenia or other psychotic disorders, acute or chronic suicidality, acute or chronic unstable medical conditions (including severely impaired hepatic function as indicated with abnormal PT and PTT, abnormal CBC, and liver enzymes more than 50% above the upper normal range, not well controlled blood pressure) current diagnosis of substance abuse or dependence unsuccessful treatment history with paliperidone known hypersensitivity to paliperidone or any of its inactive ingredients administration of any investigational drug up to 90 days before entry into the study intake of Class 1A (e.g., quinidine, procainamid) or Class III (e.g., amiodaronme, sotalol) antiarrhythmic medications, antipsychotics, antibiotics (e.g., gatifloxacin, moxifloxacin) (up to 90 days before entry into the study or during the study) subjects with a positive screen for drugs of abuse no startle or skin conductance response, or excessively high startle response to the startle probe (100 dB acoustic stimuli) during the pretest
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Rhinitis, Allergic, Perennial Patients of mongoloid race residing in Japan who satisfy all of the following Patients having symptoms of perennial allergic rhinitis of moderate or severe degree, according to the classification of severity in the guidelines for the treatment of nasal allergy (partial revision) as well as a score of at least 4 in the score of 4 nasal symptoms, at the time of obtaining informed consent and during the pretreatment observation period Patients with a positive skin reaction test or specific IgE antibody quantitation, and with a positive cytological examination of nasal discharge (eosinophils) or nasal challenge test Outpatients who are at least 16 years of age at the time of informed consent obtained Male or female Patients who have the ability to give written informed consent (informed consent of the guardian must also be obtained for patients younger than 20 years) Patients who can keep nasal allergy diary without fail  Patients with coexisting tuberculous disease or lower respiratory tract infection, or patients who, at the time of registration, have acute upper respiratory tract infection, acute pharyngitis, acute amygdalitis etc Patients with coexisting infections or systemic mycosis for which there are no effective antibiotics Patients with unhealed nasal septum ulcers, nasal surgery scar, or nasal trauma Patients with a history of hypersensitivity to steroids or mometasone furoate Patients who are pregnant or nursing or who may be pregnant and patients or patients' partners who desire to become pregnant during the study period Patients with severe hepatic, renal, cardiac, hematological disease, diabetes mellitus, hypertension or other serious coexisting diseases and whose general condition is poor Patients also allergic to pollen and the pollen release season occurs during the study period Patients with vasomotor rhinitis or eosinophilic rhinitis Patients with a nasal condition which may interfere with efficacy evaluation of the investigational product Patients who develop disease affecting nasal symptoms during the pretreatment observation period, i.e., during the 7 days before actual registration
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Perennial Allergic Rhinitis Patients with perennial allergic rhinitis meeting all of the followings Patients with symptoms of perennial allergic rhinitis, the severity of which is moderate or severer according to the severity grading provided in the "Guidelines for the Management of Allergic Rhinitis in Japan" (partly modified) with the 4-nasal symptom score of 4 or over at informed consent and during the pre-treatment observation period Patients with positive reaction to the eosinophil count in nasal discharge or nasal challenge test in addition to the skin test or specific IgE antibody test Outpatients aged 16 years or over at informed consent Patients in either sex Patients (or their legal representatives in case of patients aged under 20 years) capable of giving written informed consent Patients capable of recording nasal allergy diary every day  Patients with a complication of tuberculous diseases or lower respiratory tract infections, and those with a complication of otorhinolaryngeal infections(acute upper respiratory tract inflammation, acute laryngopharyngitis, acute tonsillitis, etc.) requiring treatments judged by the investigator (subinvestigator) at the time of enrollment to randomization Patients with a complication of infection or systemic mycosis for which no effective antibiotics are available Patients with a complication of recurrent epistaxis Patients with uncured nasal septal ulcer, operated nose or nasal trauma Patients with a history of hypersensitivity to steroids and any ingredients of the study drugs Pregnant, lactating or possibly pregnant patients or the patients who themselves or whose partners wish to become pregnant during the study Patients with severe hepatic or renal disorder, heart or blood disease, diabetes mellitus, hypertension, or other serious complication, suffering from problems with systemic condition Patients who have pollens as multiple allergens and the period from 7 days before enrollment to randomization to completion of the treatment period coincides with the period of scattering of relevant pollens Patients with a complication of vasomotor rhinitis or eosinophilic rhinitis Patients with a complication of a nasal disease (infectious sinusitis, hypertrophic rhinitis, acute or chronic rhinitis, nasal polyps, or septal deviation) which may interfere with efficacy evaluation of the study drugs
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  West Nile Neuroinvasive Disease West Nile Virus Infection Encephalitis Meningitis Acute Flaccid Paralysis West Nile Fever Provide written informed consent Be >=18 years of age at the time of enrollment Have West Nile Fever defined as temperature >38°C, headache, AND positive diagnostic test for WNV Ribonucleic acid or Immunoglobulin M with serum or cerebrospinal fluid (CSF) OR have West Nile Neuroinvasive Disease (includes neurological signs and/or symptoms of West Nile meningitis, encephalitis, and/or acute flaccid paralysis), defined as • West Nile encephalitis (must meet a and b below) Encephalopathy (depressed or altered level of consciousness, lethargy, or personality change lasting 24 hours) CSF pleocytosis >=5 cells/mm^3 AND/OR
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Brain and Central Nervous System Tumors Breast Cancer Metastatic Cancer Meets 1 of the following Diagnosis of metastatic breast cancer with evidence suggestive of carcinomatous meningitis, with or without brain metastasis Other type of cancer with evidence suggestive of carcinomatous meningitis Meningeal syndrome without context of cancer No other prior cancers Not pregnant or nursing No prior intrathecal treatment At least 4 weeks since prior interferon No concurrent participation in another clinical trial
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Vasomotor Rhinitis Diagnosis of VMR with at least 2 years of chronic non-allergic rhinitis Negative skin tests to a panel of allergens and positive histamine test within last 2 years History of symptoms related to defined VMR triggers  Nasal disorder, surgery, or concurrent disease that could interfere with evaluation of study medications Bacterial or viral infection within 14 days of first visit. Diagnosis of acute sinusitis within 30 days of first visit Chronic use of drugs that can cause rhinitis
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 5.0-15.0,  Rhinitis, Allergic, Perennial Pediatric subjects with perennial allergic rhinitis who satisfy all of the following main Subjects having symptoms of perennial allergic rhinitis of moderate to severe degree, after the pretreatment observation period Subjects confirmed to be allergic to non-seasonal environmental antigens (e.g., house dust-mite antigen) Male or female outpatients aged 5 to 15 years at the time of providing informed consent  Subjects for whom any of the main below is applicable will not be registered in this study Subjects with coexisting tuberculous disease or lower respiratory tract infection and subjects who have a nasopharyngolaryngeal infection (acute upper respiratory tract infection, acute pharyngolaryngitis, or acute tonsillitis, etc.) requiring treatment at the time of registration Subjects with coexisting infections or systemic mycosis for which there are no effective antibiotics Subjects with repeated epistaxis Subjects who have nasal septum ulcers, nasal surgery, or nasal trauma, which have not healed Subjects with severe hepatic, renal, cardiac, hematological disease, diabetes mellitus, hypertension, or other serious coexisting diseases and whose general condition is poor Subjects with complication of vasomotor rhinitis or eosinophilic rhinitis Subjects with nasal conditions (infectious sinusitis, hypertrophic rhinitis, acute or chronic rhinitis, nasal polyps, septal deviation, etc.) which may interfere with the evaluation of the efficacy of the study drug
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Brain Injuries, Traumatic Injuries, Acute Brain TBI (Traumatic Brain Injury) Adults and children with physical trauma who: 1) are transported directly to or are transferred to a level I TC by participating EMS agencies, 2) have hospital diagnosis(es) consistent with TBI (either isolated or multisystem trauma that includes TBI), and 3) meet at least one of the following definitions for severe TBI: a) last prehospital GCS or first hospital/trauma center GCS <9; b) AIS-head of ≥3, c) CDC Barell Matrix-Type 1, d) undergo prehospital ETI, nasal intubation, or cricothyrotomy  Patients with brain injury from: 1) non-mechanical mechanisms (e.g., drowning); 2) choking, primary asphyxiation, or strangulation; 3) environmental injury (e.g., hyperthermia); 4) poisoning (e.g., drug overdose, carbon monoxide, insecticides); 5) intracranial hemorrhage of non-traumatic origin; 6) other non-traumatic, acute neurological emergencies (e.g., bacterial meningitis)
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cerebrospinal Fluid Leaks Main (Positive response) • Is the surgical approach/procedure consistent with skull base surgery? I.e. one of the following Lateral approach to the foramen magnum: Far lateral, extreme lateral, anterolateral, posterolateral Approach to the jugular foramen: Infratemporal, juxta condylar, transjugular Approach to the cerebello pontine (CP) angle and petrous apex retrosigmoid Approach to the middle fossa: Subtemporal (+/ petrous apex drilling), pterional approach (any fronto temporal approach +/ orbitozygomatic deposition) Approach to the anterior fossa: Subfrontal (uni or bilateral) Approach to the midline posterior fossa  (Negative response) Has the patient been subject to neurosurgery involving opening of the dura mater within the last 3 months? Is the patient anticipated to undergo any additional neurosurgery involving opening of the dura mater which may affect the efficacy evaluation (e.g. re-operation or anticipation to undergo several neurosurgeries) before the Efficacy Follow-up Week 7±1 week? Is the patient anticipated to undergo any additional neurosurgery involving opening of the dura mater which may affect the safety evaluation (e.g. re-operation or anticipation to undergo several neurosurgeries) before the Safety Follow-up Week 28±2 weeks? The surgical approach/procedure is consistent with any transcranial or transfacial or combination of transcranial transfacial approaches with wide defect in the skull base? I.e. any of the following Trans basal approach Total petrosectomy Trans facial approach Trans sphenoidal approach
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Perennial Rhinitis Seasonal Rhinitis All patients have to sign the informed consent or give verbal confirmation prior to their in the study Outpatient (external) male or female over 18 years and under 50 years Patients with active rhinitis (anterior or posterior rhinorrhea, sneezing, nasal congestion and itching) persistent (≥ 4 days a week for 4 consecutive weeks) or intermittent (< 4 days a week for ≤ 4 consecutive weeks) Patient with medical history of rhinitis 2 years prior to their participation in this study and whose nasal symptoms have been severe enough to require continuous or intermittent treatment (it requires a patient's symptoms need treatment at least for a 4 weeks period) Patient with the ability to understand the risks and benefits requirement while participating in the study and is able to accomplish the study treatment and with filling questionnaires and patient's diaries  Patient with other nasal disease including: nasal polyps or nasal trauma recent Patient with intranasal malformations (cysts and fistulas of the nose dorsum, prenasal space malformation, midline dystrophy, arrhinea, abnormalities of the tear ducts), or other conditions such as; recent nasal biopsy, drug rhinitis Non-controlled asthma or who were under systemic corticosteroid treatment Patient with Chronic Obstructive Pulmonary Disease Medical history of respiratory infection or other disease including bronchitis, pneumonia, common cold, acute or chronic sinusitis, influenza, etc. within 30 days prior to its in the study Patient receiving antibiotic therapy for any acute illness during the past 14 days Patient vaccinated against pneumococcus, H1N1 & seasonal influenza (past 30 days) Patient required initiation or dose escalation immunotherapy. Immunotherapy is permitted if started 90 days ago and the patient received a stable dose during the last 30 days Patient has participated in another research study within 30 days preceding this visit Patient with medical history of hypersensitivity to steroids or any excipients of this class of drugs